RFA+Highly-purified CTL vs. RFA Alone for Recurrent HCC

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Clinical Phase

PHASE3

Total Enrollment

210 participants

Study Classification

INTERVENTIONAL

Study Start Date

2016-02-29

Study Completion Date

2022-01-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Hepatocellular carcinoma (HCC) is the fifth most common and the third leading cause of cancer-related death worldwide. Recurrence of tumor within the liver remnant is common, with a reported 5-year recurrence rate of 70%. Repeat hepatectomy is an effective treatment for intrahepatic HCC but with a small proportion of resection rate because of the poor functional liver reserve and postoperative complications. Radiofrequency ablation(RFA) is becoming the main effective treatment for small HCC (≤5.0cm). The efficacy of RFA for recurrent HCC has been reported to be comparable to those achieved by surgery with minimal, but higher local recurrence rate after RFA. It has been reported that immunotherapy in patients who underwent curative treatment for HCC, adjuvant immunotherapy with activated CIK cells increased recurrence-free and overall survival. But there is little evidence for adjuvant immunotherapy of recurrence HCC. Cytotoxic T lymphocytes(CTL), a kind of effective T cells that specific recognizing and killing antigen targeted cells through cloning amplification after receiving antigen information from antigen presented cell and playing key role to clear cancerous cells. So our hypothesis is that RFA combined with immunotherapy (Highly-purified CTL) is superior to RFA for recurrent HCC. The aim of this prospective study is to compare the outcome of RFA combined with immunotherapy (Highly-purified CTL) with RFA for small recurrent HCC after partial hepatectomy.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

TACE+RFA Versus Re-resection for Recurrent Small Hepatocellular Carcinoma

NCT01833286

Hepatocellular Carcinoma Surgery Ablation

UNKNOWN PHASE3

Percutaneous Radiofrequency Ablation Versus Repeat Hepatectomy for Recurrent Hepatocellular Carcinoma

NCT01570166

Hepatocellular Carcinoma

UNKNOWN NA

HR Versus RFA for Early Stage HCC

NCT02169765

Hepatocellular Carcinoma Liver Cancer

UNKNOWN PHASE3

Radiofrequency Ablation Versus Liver Resection for Elderly Patients With Hepatocellular Carcinoma (HCC) Within the Milan Criteria

NCT01570075

Hepatocellular Carcinoma

UNKNOWN PHASE4

RFA Versus SBRT for Recurrent Small HCC

NCT04047173

Hepatocellular Carcinoma

COMPLETED PHASE3

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Hepatocellular Carcinoma

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Radiofrequency ablation(RFA)

RFA was performed according to the Guidelines of Radiofrequency Ablation Therapy for Liver Cancer: Chinese Expert Consensus Statement issued by the Chinese Society of Liver Cancer and Chinese Society of Clinical Oncology RFA was performed under real-time ultrasound guidance. RFA was performed by using a commercially available Cool-tipTM RFA system (Valleylab, Boulder, CO, USA), or a RF 2000 system (Radio-Therapeutics Mountain View, CA). Grounding was achieved by attaching 2 pads to the patient's back or legs.

Group Type EXPERIMENTAL

RFA

Intervention Type PROCEDURE

Radiofrequency ablation(RFA)for small recurrent HCC

RFA+CTL

RFA was performed the same as RFA Arm.Peripheral blood (20-30mL) for manufacturing the individualized highly-purified CTL agent was collected from the respective patients who were randomized to the immunotherapy group before starting treatment. The highly-purified CTL agent was prepared at a central manufacturing facility. Patients in the immunotherapy group received 5\*10E9 of the highly-purified CTL agent intravenously over 60 minutes without any premedication and then were observed for at least 30 minutes. They were scheduled to receive highly-purified CTL: 4-6 treatments at a frequency of once two-week during 6 months after receiving RFA, followed by 6-9 treatments during 6 months to 2 years after receiving RFA.

Group Type ACTIVE_COMPARATOR

RFA+highly-purified CTL

Intervention Type PROCEDURE

Radiofrequency ablation(RFA) plus highly-purified CTL for small recurrent HCC

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

RFA

Radiofrequency ablation(RFA)for small recurrent HCC

Intervention Type PROCEDURE

RFA+highly-purified CTL

Radiofrequency ablation(RFA) plus highly-purified CTL for small recurrent HCC

Intervention Type PROCEDURE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. age 18-75 years;
2. recurrence of HCC 12 months after initial hepatectomy;
3. no other treatment received except for the initial hepatectomy;
4. single tumor≤5.0cm in diameter; or 2-3 lesions each≤3.0cm;
5. lesions visible on ultrasound and with an acceptable and safe path between the lesion and the skin as shown on ultrasound;
6. no severe coagulation disorders (prothrombin activity\<40% or a platelet count\<40,000/mm3);
7. Eastern Co-operative Oncology Group performance(ECOG) status 0-1.

Exclusion Criteria

1. Pregnant women, breastfeeding women or plan pregnancy for the future 2 years;
2. The presence of vascular invasion or extrahepatic spread onimaging;
3. Usage of strong immunosuppressive agents such as corticosteroids, cyclosporine A within six months or longer;
4. HIV antibody or HCV antibody positive;
5. Immunodeficiency diseases or autoimmune diseases (such as rheumatoid arthritis, Buerger's disease, multiple sclerosis and type 1 diabetes);
6. Suffering with cancers (except skin cancer, prostate cancer or cervical carcinoma in situ) at the enrolling time or 5 years before;
7. Suffering with other organ failure;
8. Suffering with severe mental illness;
9. Drug addiction (including alcohol) for 1 year before the enrolling time;
10. Participate in other Clinical trials within three months prior to 3 months before the enrolling time;
11. Other researchers believe that the patient is not fit for inclusion.

Minimum Eligible Age

18 Years

Maximum Eligible Age

75 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No